269 related articles for article (PubMed ID: 24155386)
21. Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines.
Zhang X; Zhao L; Hang Z; Guo H; Zhang M
Oncol Rep; 2011 Sep; 26(3):637-44. PubMed ID: 21567107
[TBL] [Abstract][Full Text] [Related]
22. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
23. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
24. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
25. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
[TBL] [Abstract][Full Text] [Related]
27. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
29. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
30. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
32. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
[TBL] [Abstract][Full Text] [Related]
33. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O; Morris JC
J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
[TBL] [Abstract][Full Text] [Related]
34. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
35. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.
Davis JJ; Wang L; Dong F; Zhang L; Guo W; Teraishi F; Xu K; Ji L; Fang B
Cancer Gene Ther; 2006 Jul; 13(7):720-3. PubMed ID: 16485010
[TBL] [Abstract][Full Text] [Related]
36. In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.
Adamson RE; Frazier AA; Evans H; Chambers KF; Schenk E; Essand M; Birnie R; Mitry RR; Dhawan A; Maitland NJ
Hum Gene Ther; 2012 Feb; 23(2):218-30. PubMed ID: 21823897
[TBL] [Abstract][Full Text] [Related]
37. [Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6].
Wang Q; Wang YH; Li Y; Xing M; Zhou DM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):71-76. PubMed ID: 35048603
[TBL] [Abstract][Full Text] [Related]
38. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
39. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
[TBL] [Abstract][Full Text] [Related]
40. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
